Psoriasis activity (the PASI score), folate concentrations in the plasma and red blood cells as well as plasma homocysteine were followed during the initial period of treatment of moderate-severe to severe psoriasis with low-dose oral methotrexate. Patients were randomized into two treatment arms: A (MTX week 1-16, MTX + folic acid week 17- 32) and B (MTX + folic acid week 1-16, MTX week 17- 32).
In the study arm A, the percent improvemet of PASI was lower than in the arm B (42%(SEM 10%) vs. 73% (SEM 7%), P<0.01). In the study arm B, however, the folate levels decreased and plasma homocysteine increased and more side effects were recorded.
Folic acid (20 mg/week) decreases therapeutic effect as well as side effects of methotrexate.